1
|
Hiddemann W, Barbui AM, Canales MA, Cannell PK, Collins GP, Dürig J, Forstpointner R, Herold M, Hertzberg M, Klanova M, Radford J, Seymour JF, Tobinai K, Trotman J, Burciu A, Fingerle-Rowson G, Wolbers M, Nielsen T, Marcus RE. Immunochemotherapy With Obinutuzumab or Rituximab for Previously Untreated Follicular Lymphoma in the GALLIUM Study: Influence of Chemotherapy on Efficacy and Safety. J Clin Oncol 2018; 36:2395-2404. [PMID: 29856692 DOI: 10.1200/jco.2017.76.8960] [Citation(s) in RCA: 144] [Impact Index Per Article: 24.0] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
Purpose The GALLIUM study ( ClinicalTrials.gov identifier: NCT01332968) showed that obinutuzumab (GA101; G) significantly prolonged progression-free survival (PFS) in previously untreated patients with follicular lymphoma relative to rituximab (R) when combined with cyclophosphamide (C), doxorubicin, vincristine (V), and prednisone (P; CHOP); CVP; or bendamustine. This report focuses on the impact of chemotherapy backbone on efficacy and safety. Patients and Methods A total of 1,202 patients with previously untreated follicular lymphoma (grades 1 to 3a), advanced disease (stage III or IV, or stage II with tumor diameter ≥ 7 cm), Eastern Cooperative Oncology Group performance status 0 to 2, and requiring treatment were randomly assigned 1:1 to G 1,000 mg on days 1, 8, and 15 of cycle 1 and day 1 of subsequent cycles or R 375 mg/m2 on day 1 of each cycle, for six to eight cycles, depending on chemotherapy (allocated nonrandomly by center). Responding patients received G or R for 2 years or until disease progression. Results Baseline Follicular Lymphoma International Prognostic Index risk, bulky disease, and comorbidities differed by chemotherapy. After 41.1 months median follow-up, PFS (primary end point) was superior for G plus chemotherapy (overall hazard ratio [HR], 0.68; 95% CI, 0.54 to 0.87; P = .0016), with consistent results across chemotherapy backbones (bendamustine: HR, 0.63; 95% CI, 0.46 to 0.88; CHOP: HR, 0.72; 95% CI, 0.48 to 1.10; CVP: HR, 0.79; 95% CI, 0.42 to 1.47). Grade 3 to 5 adverse events, notably cytopenias, were most frequent with CHOP. Grade 3 to 5 infections and second neoplasms were most frequent with bendamustine, which was associated with marked and prolonged reductions in T-cell counts. Fatal events were more frequent in patients treated with bendamustine, possibly reflecting differences in patient risk profiles. Conclusion Improved PFS was observed for G plus chemotherapy for all three chemotherapy backbones. Safety profiles differed, although comparisons are confounded by nonrandom chemotherapy allocation.
Collapse
Affiliation(s)
- Wolfgang Hiddemann
- Wolfgang Hiddemann and Roswitha Forstpointner, University Hospital, Ludwig Maximilian University Munich, Munich; Jan Dürig, University Hospital Essen, Essen; Michael Herold, HELIOS-Klinikum Erfurt, Erfurt, Germany; Anna Maria Barbui, Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, Italy; Miguel A. Canales, Hospital Universitario la Paz, Madrid, Spain; Paul K. Cannell, Fiona Stanley Hospital, Murdoch, Western Australia; Mark Hertzberg, Prince of Wales Hospital; Judith Trotman, Concord Repatriation General Hospital, University of Sydney, Sydney, New South Wales; John F. Seymour, Royal Melbourne Hospital, and University of Melbourne, Melbourne, Victoria, Australia; Graham P. Collins, Churchill Hospital, Oxford; John Radford, University of Manchester and the Christie National Health Service Foundation Trust, Manchester Academic Health Science Centre, Manchester; Robert E. Marcus, Kings College Hospital, London, United Kingdom; Magdalena Klanova, Charles University General Hospital, Prague, Czech Republic; Magdalena Klanova, Alis Burciu, Günter Fingerle-Rowson, Marcel Wolbers, and Tina Nielsen, F. Hoffmann-La Roche, Basel, Switzerland; and Kensei Tobinai, National Cancer Center Hospital, Tokyo, Japan
| | - Anna Maria Barbui
- Wolfgang Hiddemann and Roswitha Forstpointner, University Hospital, Ludwig Maximilian University Munich, Munich; Jan Dürig, University Hospital Essen, Essen; Michael Herold, HELIOS-Klinikum Erfurt, Erfurt, Germany; Anna Maria Barbui, Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, Italy; Miguel A. Canales, Hospital Universitario la Paz, Madrid, Spain; Paul K. Cannell, Fiona Stanley Hospital, Murdoch, Western Australia; Mark Hertzberg, Prince of Wales Hospital; Judith Trotman, Concord Repatriation General Hospital, University of Sydney, Sydney, New South Wales; John F. Seymour, Royal Melbourne Hospital, and University of Melbourne, Melbourne, Victoria, Australia; Graham P. Collins, Churchill Hospital, Oxford; John Radford, University of Manchester and the Christie National Health Service Foundation Trust, Manchester Academic Health Science Centre, Manchester; Robert E. Marcus, Kings College Hospital, London, United Kingdom; Magdalena Klanova, Charles University General Hospital, Prague, Czech Republic; Magdalena Klanova, Alis Burciu, Günter Fingerle-Rowson, Marcel Wolbers, and Tina Nielsen, F. Hoffmann-La Roche, Basel, Switzerland; and Kensei Tobinai, National Cancer Center Hospital, Tokyo, Japan
| | - Miguel A Canales
- Wolfgang Hiddemann and Roswitha Forstpointner, University Hospital, Ludwig Maximilian University Munich, Munich; Jan Dürig, University Hospital Essen, Essen; Michael Herold, HELIOS-Klinikum Erfurt, Erfurt, Germany; Anna Maria Barbui, Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, Italy; Miguel A. Canales, Hospital Universitario la Paz, Madrid, Spain; Paul K. Cannell, Fiona Stanley Hospital, Murdoch, Western Australia; Mark Hertzberg, Prince of Wales Hospital; Judith Trotman, Concord Repatriation General Hospital, University of Sydney, Sydney, New South Wales; John F. Seymour, Royal Melbourne Hospital, and University of Melbourne, Melbourne, Victoria, Australia; Graham P. Collins, Churchill Hospital, Oxford; John Radford, University of Manchester and the Christie National Health Service Foundation Trust, Manchester Academic Health Science Centre, Manchester; Robert E. Marcus, Kings College Hospital, London, United Kingdom; Magdalena Klanova, Charles University General Hospital, Prague, Czech Republic; Magdalena Klanova, Alis Burciu, Günter Fingerle-Rowson, Marcel Wolbers, and Tina Nielsen, F. Hoffmann-La Roche, Basel, Switzerland; and Kensei Tobinai, National Cancer Center Hospital, Tokyo, Japan
| | - Paul K Cannell
- Wolfgang Hiddemann and Roswitha Forstpointner, University Hospital, Ludwig Maximilian University Munich, Munich; Jan Dürig, University Hospital Essen, Essen; Michael Herold, HELIOS-Klinikum Erfurt, Erfurt, Germany; Anna Maria Barbui, Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, Italy; Miguel A. Canales, Hospital Universitario la Paz, Madrid, Spain; Paul K. Cannell, Fiona Stanley Hospital, Murdoch, Western Australia; Mark Hertzberg, Prince of Wales Hospital; Judith Trotman, Concord Repatriation General Hospital, University of Sydney, Sydney, New South Wales; John F. Seymour, Royal Melbourne Hospital, and University of Melbourne, Melbourne, Victoria, Australia; Graham P. Collins, Churchill Hospital, Oxford; John Radford, University of Manchester and the Christie National Health Service Foundation Trust, Manchester Academic Health Science Centre, Manchester; Robert E. Marcus, Kings College Hospital, London, United Kingdom; Magdalena Klanova, Charles University General Hospital, Prague, Czech Republic; Magdalena Klanova, Alis Burciu, Günter Fingerle-Rowson, Marcel Wolbers, and Tina Nielsen, F. Hoffmann-La Roche, Basel, Switzerland; and Kensei Tobinai, National Cancer Center Hospital, Tokyo, Japan
| | - Graham P Collins
- Wolfgang Hiddemann and Roswitha Forstpointner, University Hospital, Ludwig Maximilian University Munich, Munich; Jan Dürig, University Hospital Essen, Essen; Michael Herold, HELIOS-Klinikum Erfurt, Erfurt, Germany; Anna Maria Barbui, Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, Italy; Miguel A. Canales, Hospital Universitario la Paz, Madrid, Spain; Paul K. Cannell, Fiona Stanley Hospital, Murdoch, Western Australia; Mark Hertzberg, Prince of Wales Hospital; Judith Trotman, Concord Repatriation General Hospital, University of Sydney, Sydney, New South Wales; John F. Seymour, Royal Melbourne Hospital, and University of Melbourne, Melbourne, Victoria, Australia; Graham P. Collins, Churchill Hospital, Oxford; John Radford, University of Manchester and the Christie National Health Service Foundation Trust, Manchester Academic Health Science Centre, Manchester; Robert E. Marcus, Kings College Hospital, London, United Kingdom; Magdalena Klanova, Charles University General Hospital, Prague, Czech Republic; Magdalena Klanova, Alis Burciu, Günter Fingerle-Rowson, Marcel Wolbers, and Tina Nielsen, F. Hoffmann-La Roche, Basel, Switzerland; and Kensei Tobinai, National Cancer Center Hospital, Tokyo, Japan
| | - Jan Dürig
- Wolfgang Hiddemann and Roswitha Forstpointner, University Hospital, Ludwig Maximilian University Munich, Munich; Jan Dürig, University Hospital Essen, Essen; Michael Herold, HELIOS-Klinikum Erfurt, Erfurt, Germany; Anna Maria Barbui, Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, Italy; Miguel A. Canales, Hospital Universitario la Paz, Madrid, Spain; Paul K. Cannell, Fiona Stanley Hospital, Murdoch, Western Australia; Mark Hertzberg, Prince of Wales Hospital; Judith Trotman, Concord Repatriation General Hospital, University of Sydney, Sydney, New South Wales; John F. Seymour, Royal Melbourne Hospital, and University of Melbourne, Melbourne, Victoria, Australia; Graham P. Collins, Churchill Hospital, Oxford; John Radford, University of Manchester and the Christie National Health Service Foundation Trust, Manchester Academic Health Science Centre, Manchester; Robert E. Marcus, Kings College Hospital, London, United Kingdom; Magdalena Klanova, Charles University General Hospital, Prague, Czech Republic; Magdalena Klanova, Alis Burciu, Günter Fingerle-Rowson, Marcel Wolbers, and Tina Nielsen, F. Hoffmann-La Roche, Basel, Switzerland; and Kensei Tobinai, National Cancer Center Hospital, Tokyo, Japan
| | - Roswitha Forstpointner
- Wolfgang Hiddemann and Roswitha Forstpointner, University Hospital, Ludwig Maximilian University Munich, Munich; Jan Dürig, University Hospital Essen, Essen; Michael Herold, HELIOS-Klinikum Erfurt, Erfurt, Germany; Anna Maria Barbui, Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, Italy; Miguel A. Canales, Hospital Universitario la Paz, Madrid, Spain; Paul K. Cannell, Fiona Stanley Hospital, Murdoch, Western Australia; Mark Hertzberg, Prince of Wales Hospital; Judith Trotman, Concord Repatriation General Hospital, University of Sydney, Sydney, New South Wales; John F. Seymour, Royal Melbourne Hospital, and University of Melbourne, Melbourne, Victoria, Australia; Graham P. Collins, Churchill Hospital, Oxford; John Radford, University of Manchester and the Christie National Health Service Foundation Trust, Manchester Academic Health Science Centre, Manchester; Robert E. Marcus, Kings College Hospital, London, United Kingdom; Magdalena Klanova, Charles University General Hospital, Prague, Czech Republic; Magdalena Klanova, Alis Burciu, Günter Fingerle-Rowson, Marcel Wolbers, and Tina Nielsen, F. Hoffmann-La Roche, Basel, Switzerland; and Kensei Tobinai, National Cancer Center Hospital, Tokyo, Japan
| | - Michael Herold
- Wolfgang Hiddemann and Roswitha Forstpointner, University Hospital, Ludwig Maximilian University Munich, Munich; Jan Dürig, University Hospital Essen, Essen; Michael Herold, HELIOS-Klinikum Erfurt, Erfurt, Germany; Anna Maria Barbui, Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, Italy; Miguel A. Canales, Hospital Universitario la Paz, Madrid, Spain; Paul K. Cannell, Fiona Stanley Hospital, Murdoch, Western Australia; Mark Hertzberg, Prince of Wales Hospital; Judith Trotman, Concord Repatriation General Hospital, University of Sydney, Sydney, New South Wales; John F. Seymour, Royal Melbourne Hospital, and University of Melbourne, Melbourne, Victoria, Australia; Graham P. Collins, Churchill Hospital, Oxford; John Radford, University of Manchester and the Christie National Health Service Foundation Trust, Manchester Academic Health Science Centre, Manchester; Robert E. Marcus, Kings College Hospital, London, United Kingdom; Magdalena Klanova, Charles University General Hospital, Prague, Czech Republic; Magdalena Klanova, Alis Burciu, Günter Fingerle-Rowson, Marcel Wolbers, and Tina Nielsen, F. Hoffmann-La Roche, Basel, Switzerland; and Kensei Tobinai, National Cancer Center Hospital, Tokyo, Japan
| | - Mark Hertzberg
- Wolfgang Hiddemann and Roswitha Forstpointner, University Hospital, Ludwig Maximilian University Munich, Munich; Jan Dürig, University Hospital Essen, Essen; Michael Herold, HELIOS-Klinikum Erfurt, Erfurt, Germany; Anna Maria Barbui, Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, Italy; Miguel A. Canales, Hospital Universitario la Paz, Madrid, Spain; Paul K. Cannell, Fiona Stanley Hospital, Murdoch, Western Australia; Mark Hertzberg, Prince of Wales Hospital; Judith Trotman, Concord Repatriation General Hospital, University of Sydney, Sydney, New South Wales; John F. Seymour, Royal Melbourne Hospital, and University of Melbourne, Melbourne, Victoria, Australia; Graham P. Collins, Churchill Hospital, Oxford; John Radford, University of Manchester and the Christie National Health Service Foundation Trust, Manchester Academic Health Science Centre, Manchester; Robert E. Marcus, Kings College Hospital, London, United Kingdom; Magdalena Klanova, Charles University General Hospital, Prague, Czech Republic; Magdalena Klanova, Alis Burciu, Günter Fingerle-Rowson, Marcel Wolbers, and Tina Nielsen, F. Hoffmann-La Roche, Basel, Switzerland; and Kensei Tobinai, National Cancer Center Hospital, Tokyo, Japan
| | - Magdalena Klanova
- Wolfgang Hiddemann and Roswitha Forstpointner, University Hospital, Ludwig Maximilian University Munich, Munich; Jan Dürig, University Hospital Essen, Essen; Michael Herold, HELIOS-Klinikum Erfurt, Erfurt, Germany; Anna Maria Barbui, Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, Italy; Miguel A. Canales, Hospital Universitario la Paz, Madrid, Spain; Paul K. Cannell, Fiona Stanley Hospital, Murdoch, Western Australia; Mark Hertzberg, Prince of Wales Hospital; Judith Trotman, Concord Repatriation General Hospital, University of Sydney, Sydney, New South Wales; John F. Seymour, Royal Melbourne Hospital, and University of Melbourne, Melbourne, Victoria, Australia; Graham P. Collins, Churchill Hospital, Oxford; John Radford, University of Manchester and the Christie National Health Service Foundation Trust, Manchester Academic Health Science Centre, Manchester; Robert E. Marcus, Kings College Hospital, London, United Kingdom; Magdalena Klanova, Charles University General Hospital, Prague, Czech Republic; Magdalena Klanova, Alis Burciu, Günter Fingerle-Rowson, Marcel Wolbers, and Tina Nielsen, F. Hoffmann-La Roche, Basel, Switzerland; and Kensei Tobinai, National Cancer Center Hospital, Tokyo, Japan
| | - John Radford
- Wolfgang Hiddemann and Roswitha Forstpointner, University Hospital, Ludwig Maximilian University Munich, Munich; Jan Dürig, University Hospital Essen, Essen; Michael Herold, HELIOS-Klinikum Erfurt, Erfurt, Germany; Anna Maria Barbui, Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, Italy; Miguel A. Canales, Hospital Universitario la Paz, Madrid, Spain; Paul K. Cannell, Fiona Stanley Hospital, Murdoch, Western Australia; Mark Hertzberg, Prince of Wales Hospital; Judith Trotman, Concord Repatriation General Hospital, University of Sydney, Sydney, New South Wales; John F. Seymour, Royal Melbourne Hospital, and University of Melbourne, Melbourne, Victoria, Australia; Graham P. Collins, Churchill Hospital, Oxford; John Radford, University of Manchester and the Christie National Health Service Foundation Trust, Manchester Academic Health Science Centre, Manchester; Robert E. Marcus, Kings College Hospital, London, United Kingdom; Magdalena Klanova, Charles University General Hospital, Prague, Czech Republic; Magdalena Klanova, Alis Burciu, Günter Fingerle-Rowson, Marcel Wolbers, and Tina Nielsen, F. Hoffmann-La Roche, Basel, Switzerland; and Kensei Tobinai, National Cancer Center Hospital, Tokyo, Japan
| | - John F Seymour
- Wolfgang Hiddemann and Roswitha Forstpointner, University Hospital, Ludwig Maximilian University Munich, Munich; Jan Dürig, University Hospital Essen, Essen; Michael Herold, HELIOS-Klinikum Erfurt, Erfurt, Germany; Anna Maria Barbui, Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, Italy; Miguel A. Canales, Hospital Universitario la Paz, Madrid, Spain; Paul K. Cannell, Fiona Stanley Hospital, Murdoch, Western Australia; Mark Hertzberg, Prince of Wales Hospital; Judith Trotman, Concord Repatriation General Hospital, University of Sydney, Sydney, New South Wales; John F. Seymour, Royal Melbourne Hospital, and University of Melbourne, Melbourne, Victoria, Australia; Graham P. Collins, Churchill Hospital, Oxford; John Radford, University of Manchester and the Christie National Health Service Foundation Trust, Manchester Academic Health Science Centre, Manchester; Robert E. Marcus, Kings College Hospital, London, United Kingdom; Magdalena Klanova, Charles University General Hospital, Prague, Czech Republic; Magdalena Klanova, Alis Burciu, Günter Fingerle-Rowson, Marcel Wolbers, and Tina Nielsen, F. Hoffmann-La Roche, Basel, Switzerland; and Kensei Tobinai, National Cancer Center Hospital, Tokyo, Japan
| | - Kensei Tobinai
- Wolfgang Hiddemann and Roswitha Forstpointner, University Hospital, Ludwig Maximilian University Munich, Munich; Jan Dürig, University Hospital Essen, Essen; Michael Herold, HELIOS-Klinikum Erfurt, Erfurt, Germany; Anna Maria Barbui, Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, Italy; Miguel A. Canales, Hospital Universitario la Paz, Madrid, Spain; Paul K. Cannell, Fiona Stanley Hospital, Murdoch, Western Australia; Mark Hertzberg, Prince of Wales Hospital; Judith Trotman, Concord Repatriation General Hospital, University of Sydney, Sydney, New South Wales; John F. Seymour, Royal Melbourne Hospital, and University of Melbourne, Melbourne, Victoria, Australia; Graham P. Collins, Churchill Hospital, Oxford; John Radford, University of Manchester and the Christie National Health Service Foundation Trust, Manchester Academic Health Science Centre, Manchester; Robert E. Marcus, Kings College Hospital, London, United Kingdom; Magdalena Klanova, Charles University General Hospital, Prague, Czech Republic; Magdalena Klanova, Alis Burciu, Günter Fingerle-Rowson, Marcel Wolbers, and Tina Nielsen, F. Hoffmann-La Roche, Basel, Switzerland; and Kensei Tobinai, National Cancer Center Hospital, Tokyo, Japan
| | - Judith Trotman
- Wolfgang Hiddemann and Roswitha Forstpointner, University Hospital, Ludwig Maximilian University Munich, Munich; Jan Dürig, University Hospital Essen, Essen; Michael Herold, HELIOS-Klinikum Erfurt, Erfurt, Germany; Anna Maria Barbui, Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, Italy; Miguel A. Canales, Hospital Universitario la Paz, Madrid, Spain; Paul K. Cannell, Fiona Stanley Hospital, Murdoch, Western Australia; Mark Hertzberg, Prince of Wales Hospital; Judith Trotman, Concord Repatriation General Hospital, University of Sydney, Sydney, New South Wales; John F. Seymour, Royal Melbourne Hospital, and University of Melbourne, Melbourne, Victoria, Australia; Graham P. Collins, Churchill Hospital, Oxford; John Radford, University of Manchester and the Christie National Health Service Foundation Trust, Manchester Academic Health Science Centre, Manchester; Robert E. Marcus, Kings College Hospital, London, United Kingdom; Magdalena Klanova, Charles University General Hospital, Prague, Czech Republic; Magdalena Klanova, Alis Burciu, Günter Fingerle-Rowson, Marcel Wolbers, and Tina Nielsen, F. Hoffmann-La Roche, Basel, Switzerland; and Kensei Tobinai, National Cancer Center Hospital, Tokyo, Japan
| | - Alis Burciu
- Wolfgang Hiddemann and Roswitha Forstpointner, University Hospital, Ludwig Maximilian University Munich, Munich; Jan Dürig, University Hospital Essen, Essen; Michael Herold, HELIOS-Klinikum Erfurt, Erfurt, Germany; Anna Maria Barbui, Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, Italy; Miguel A. Canales, Hospital Universitario la Paz, Madrid, Spain; Paul K. Cannell, Fiona Stanley Hospital, Murdoch, Western Australia; Mark Hertzberg, Prince of Wales Hospital; Judith Trotman, Concord Repatriation General Hospital, University of Sydney, Sydney, New South Wales; John F. Seymour, Royal Melbourne Hospital, and University of Melbourne, Melbourne, Victoria, Australia; Graham P. Collins, Churchill Hospital, Oxford; John Radford, University of Manchester and the Christie National Health Service Foundation Trust, Manchester Academic Health Science Centre, Manchester; Robert E. Marcus, Kings College Hospital, London, United Kingdom; Magdalena Klanova, Charles University General Hospital, Prague, Czech Republic; Magdalena Klanova, Alis Burciu, Günter Fingerle-Rowson, Marcel Wolbers, and Tina Nielsen, F. Hoffmann-La Roche, Basel, Switzerland; and Kensei Tobinai, National Cancer Center Hospital, Tokyo, Japan
| | - Günter Fingerle-Rowson
- Wolfgang Hiddemann and Roswitha Forstpointner, University Hospital, Ludwig Maximilian University Munich, Munich; Jan Dürig, University Hospital Essen, Essen; Michael Herold, HELIOS-Klinikum Erfurt, Erfurt, Germany; Anna Maria Barbui, Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, Italy; Miguel A. Canales, Hospital Universitario la Paz, Madrid, Spain; Paul K. Cannell, Fiona Stanley Hospital, Murdoch, Western Australia; Mark Hertzberg, Prince of Wales Hospital; Judith Trotman, Concord Repatriation General Hospital, University of Sydney, Sydney, New South Wales; John F. Seymour, Royal Melbourne Hospital, and University of Melbourne, Melbourne, Victoria, Australia; Graham P. Collins, Churchill Hospital, Oxford; John Radford, University of Manchester and the Christie National Health Service Foundation Trust, Manchester Academic Health Science Centre, Manchester; Robert E. Marcus, Kings College Hospital, London, United Kingdom; Magdalena Klanova, Charles University General Hospital, Prague, Czech Republic; Magdalena Klanova, Alis Burciu, Günter Fingerle-Rowson, Marcel Wolbers, and Tina Nielsen, F. Hoffmann-La Roche, Basel, Switzerland; and Kensei Tobinai, National Cancer Center Hospital, Tokyo, Japan
| | - Marcel Wolbers
- Wolfgang Hiddemann and Roswitha Forstpointner, University Hospital, Ludwig Maximilian University Munich, Munich; Jan Dürig, University Hospital Essen, Essen; Michael Herold, HELIOS-Klinikum Erfurt, Erfurt, Germany; Anna Maria Barbui, Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, Italy; Miguel A. Canales, Hospital Universitario la Paz, Madrid, Spain; Paul K. Cannell, Fiona Stanley Hospital, Murdoch, Western Australia; Mark Hertzberg, Prince of Wales Hospital; Judith Trotman, Concord Repatriation General Hospital, University of Sydney, Sydney, New South Wales; John F. Seymour, Royal Melbourne Hospital, and University of Melbourne, Melbourne, Victoria, Australia; Graham P. Collins, Churchill Hospital, Oxford; John Radford, University of Manchester and the Christie National Health Service Foundation Trust, Manchester Academic Health Science Centre, Manchester; Robert E. Marcus, Kings College Hospital, London, United Kingdom; Magdalena Klanova, Charles University General Hospital, Prague, Czech Republic; Magdalena Klanova, Alis Burciu, Günter Fingerle-Rowson, Marcel Wolbers, and Tina Nielsen, F. Hoffmann-La Roche, Basel, Switzerland; and Kensei Tobinai, National Cancer Center Hospital, Tokyo, Japan
| | - Tina Nielsen
- Wolfgang Hiddemann and Roswitha Forstpointner, University Hospital, Ludwig Maximilian University Munich, Munich; Jan Dürig, University Hospital Essen, Essen; Michael Herold, HELIOS-Klinikum Erfurt, Erfurt, Germany; Anna Maria Barbui, Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, Italy; Miguel A. Canales, Hospital Universitario la Paz, Madrid, Spain; Paul K. Cannell, Fiona Stanley Hospital, Murdoch, Western Australia; Mark Hertzberg, Prince of Wales Hospital; Judith Trotman, Concord Repatriation General Hospital, University of Sydney, Sydney, New South Wales; John F. Seymour, Royal Melbourne Hospital, and University of Melbourne, Melbourne, Victoria, Australia; Graham P. Collins, Churchill Hospital, Oxford; John Radford, University of Manchester and the Christie National Health Service Foundation Trust, Manchester Academic Health Science Centre, Manchester; Robert E. Marcus, Kings College Hospital, London, United Kingdom; Magdalena Klanova, Charles University General Hospital, Prague, Czech Republic; Magdalena Klanova, Alis Burciu, Günter Fingerle-Rowson, Marcel Wolbers, and Tina Nielsen, F. Hoffmann-La Roche, Basel, Switzerland; and Kensei Tobinai, National Cancer Center Hospital, Tokyo, Japan
| | - Robert E Marcus
- Wolfgang Hiddemann and Roswitha Forstpointner, University Hospital, Ludwig Maximilian University Munich, Munich; Jan Dürig, University Hospital Essen, Essen; Michael Herold, HELIOS-Klinikum Erfurt, Erfurt, Germany; Anna Maria Barbui, Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, Italy; Miguel A. Canales, Hospital Universitario la Paz, Madrid, Spain; Paul K. Cannell, Fiona Stanley Hospital, Murdoch, Western Australia; Mark Hertzberg, Prince of Wales Hospital; Judith Trotman, Concord Repatriation General Hospital, University of Sydney, Sydney, New South Wales; John F. Seymour, Royal Melbourne Hospital, and University of Melbourne, Melbourne, Victoria, Australia; Graham P. Collins, Churchill Hospital, Oxford; John Radford, University of Manchester and the Christie National Health Service Foundation Trust, Manchester Academic Health Science Centre, Manchester; Robert E. Marcus, Kings College Hospital, London, United Kingdom; Magdalena Klanova, Charles University General Hospital, Prague, Czech Republic; Magdalena Klanova, Alis Burciu, Günter Fingerle-Rowson, Marcel Wolbers, and Tina Nielsen, F. Hoffmann-La Roche, Basel, Switzerland; and Kensei Tobinai, National Cancer Center Hospital, Tokyo, Japan
| |
Collapse
|